Bill
Bill > H0859
summary
Introduced
02/03/2026
02/03/2026
In Committee
02/03/2026
02/03/2026
Crossed Over
Passed
Dead
Introduced Session
2025-2026 Session
Bill Summary
This bill proposes to establish a Psychedelic Therapy Advisory Board and requires the Department of Health to enter into a contract with a Vermont entity to perform ibogaine clinical drug development trials.
AI Summary
This bill establishes a Psychedelic Therapy Advisory Board composed of various state officials, healthcare professionals, and individuals with lived experience to research and recommend policies regarding psychedelic therapy, including exploring pilot projects for psilocybin-assisted therapies and monitoring other states' programs. Additionally, it mandates the Department of Health to contract with a Vermont entity to conduct clinical drug development trials for ibogaine, a substance being researched for its potential to treat substance use disorders and other conditions, requiring the entity to match state funding, utilize in-state resources, and develop plans for future patient access and intellectual property sharing, with $300,000 appropriated for these trials.
Committee Categories
Health and Social Services
Sponsors (6)
Brian Cina (D)*,
Conor Casey (D),
Troy Headrick (D),
Bram Kleppner (D),
Kate Logan (D),
Jubilee McGill (D),
Last Action
Read first time and referred to the Committee on Health Care (on 02/03/2026)
Official Document
bill text
bill summary
Loading...
bill summary
Loading...
bill summary
| Document Type | Source Location |
|---|---|
| State Bill Page | https://legislature.vermont.gov/bill/status/2026/H.859 |
| BillText | https://legislature.vermont.gov/Documents/2026/Docs/BILLS/H-0859/H-0859%20As%20Introduced.pdf |
Loading...